Significance of Tumour Mass on T-lymphocyte Levels in Patients with Gastrointestinal Cancer

Overview

Journal Gut

Specialty Gastroenterology

Date 1979 Aug 1

PMID 314923

Citations 1

Authors

H S Shukla

R H Whitehead

L E Hughes

Affiliations

Soon will be listed here.

Abstract

The relationship between tumour load and immunity in gastrointestinal cancer has been studied by sequential comparison in patients whose tumour has been removed and those whose tumour was found to be inoperable. Total lymphocyte count, absolute and percentage T- and B-lymphocyte counts, effect of papain on E-rosetting cell levels, and inhibitory effect of cancer sera on E-rosette formation by normal lymphocytes have been studied in 30 patients with stomach or colorectal cancer, and 10 control patients with benign gastrointestinal disease. The examination was done on each patient before and at regular intervals after operation up to 24 weeks. Operable cases, with removal of tumour load, showed a temporary fall in total lymphocyte count and T cell counts, which returned to normal by four weeks postoperatively. Inoperable cases (15 patients) showed a progressive fall in total lymphocyte count and a relatively greater depression of T cell counts, in parallel with increasing tumour mass. E-receptor blocking factor was demonstrated in the sera of cancer patients. This factor was related to tumour mass and presumably was of tumour origin, as it persisted in the inoperable group but disappeared by 12 weeks after tumour removal. The factor explained the excess depresion of T cells over total lymphocytes, but does not explain the continuing depression of total lymphocyte count in the cancer patients.

Citing Articles

The importance of protease histochemistry in pathology.

Lojda Z Histochem J. 1985; 17(10):1063-89.

PMID: 2867067 DOI: 10.1007/BF01002534.

References

Whitehead R, Roberts G, Hughes L, Thatcher J . Importance of methodology in demonstrating depression of T-lymphocyte levels. Br J Cancer. 1978; 37(1):28-32. PMC: 2009503. DOI: 10.1038/bjc.1978.4. View

Whitehead R, Roberts G, Thatcher J, Teasdale C, Hughes L . Masking of receptors for sheep erythrocytes on human T-lymphocytes by sera from breast cancer patients. J Natl Cancer Inst. 1977; 58(6):1573-6. DOI: 10.1093/jnci/58.6.1573. View

RIDDLE P . Disturbed immune reactions following surgery. Br J Surg. 1967; 54(10):882-6. DOI: 10.1002/bjs.1800541022. View

Whittaker M, Rees K, Clark C . Reduced lymphocyte transformation in breast cancer. Lancet. 1971; 1(7705):892-3. DOI: 10.1016/s0140-6736(71)92448-2. View

Browne O, Bell J, HOLLAND P, Thornes R . Letter: Plasmapheresis and immunostimulation. Lancet. 1976; 2(7976):96. DOI: 10.1016/s0140-6736(76)92311-4. View

Whitehead R, Thatcher J, Teasdale C, Roberts G, Hughes L . T and B lymphocytes in breast cancer stage relationship and abrogation of T-lymphocyte depression by enzyme treatment in vitro. Lancet. 1976; 1(7955):330-3. DOI: 10.1016/s0140-6736(76)90085-4. View

McLaughlin 3rd A, Brooks J . A plasma factor inhibiting lymphocyte reactivity in urologic cancer patients. J Urol. 1974; 112(3):366-72. DOI: 10.1016/s0022-5347(17)59733-5. View

Keller S, IOACHIM H, Pearse T, Siletti D . Decreased T-lymphocytes in patients with mammary cancer. Am J Clin Pathol. 1976; 65(4):445-9. DOI: 10.1093/ajcp/65.4.445. View

Anthony H, Kirk J, Madsen K, MASON M, Templeman G . E and EAC rosetting lymphocytes in patients with carcinoma of bronchus I. Some parameters of the test and of its prognostic significance. Clin Exp Immunol. 1975; 20(1):29-40. PMC: 1538183. View

10.

Twomey P, Catalona W, Chretien P . Proceedings: Cellular immunity in cured cancer patients. Cancer. 1974; 33(2):435-40. DOI: 10.1002/1097-0142(197402)33:2<435::aid-cncr2820330219>3.0.co;2-a. View

11.

Chapel H . The effects of papain, trypsin and phospholipase A on rosette formation. Transplantation. 1973; 15(3):320-5. DOI: 10.1097/00007890-197303000-00009. View

12.

Babusikova O, Novotna L, Korec S, Schnekova K, Turkova D, Havrankova M . Change in the proportion of T and B lymphocytes in human malignant neoplasia in relation to the clinical stage. Neoplasma. 1975; 22(4):413-21. View

13.

Harris J, Stewart T, Sengar D, Hyslop D . Quantitation of T- and B-lymphocytes in peripheral blood of patients with solid tumours. I. Relation to other parameters of in vivo and in vitro immune competence. Can Med Assoc J. 1975; 112(8):948-52. PMC: 1956074. View

14.

Bolton P, Mander A, Davidson J, James S, Newcombe R, Hughes L . Cellular immunity in cancer: comparison of delayed hypersensitivity skin tests in three common cancers. Br Med J. 1975; 3(5974):18-20. PMC: 1673694. DOI: 10.1136/bmj.3.5974.18. View

15.

Sample W, GERTNER Jr H, Chretien P . Inhibition of phytohemagglutinin-induced in vitro lymphocyte transformation by serum from patients with carcinoma. J Natl Cancer Inst. 1971; 46(6):1291-7. View

16.

Al-Sarraf M, Sardesai S, VAITKEVICIUS V . Effect of syngeneic and allogeneic plasma on lymphocytes from cancer patients, patients with non-neoplastic diseases, and normal subjects. Cancer. 1971; 27(6):1426-32. DOI: 10.1002/1097-0142(197106)27:6<1426::aid-cncr2820270624>3.0.co;2-n. View

17.

Nelson H . Delayed hypersensitivity in cancer patients: cutaneous and in vitro lymphocyte response to specific antigens. J Natl Cancer Inst. 1969; 42(5):765-70. View

18.

Golob E, Israsena T, Quatrale A, Becker K . Effect of serum from cancer patients on homologous lymphocyte cultures. Cancer. 1969; 23(2):306-8. DOI: 10.1002/1097-0142(196902)23:2<306::aid-cncr2820230207>3.0.co;2-k. View

19.

Silk M . Effect of plasma from patients with carcinoma on in vitro lymphocyte transformation. Cancer. 1967; 20(12):2088-9. DOI: 10.1002/1097-0142(196712)20:12<2088::aid-cncr2820201205>3.0.co;2-1. View